Illumina’s PromoterAI unlocks rare disease clues in noncoding genome

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. Today, we discuss how one Brown contrarian and cancer researcher wants $50 billion for the NCI, we see a UniQure case study that shows its gene therapy helped reduce seizures, and more.

Summit Therapeutics crashes the ASCO party

As the big ASCO cancer conference kicks off today, Summit Therapeutics reported results via press release from a closely tracked study of its PD1-VEGF antibody ivonescimab. The drug delayed the progression of lung cancer in patients from the U.S. and other Western countries consistent with prior results reported from patients enrolled from China, achieving the goal of a Phase 3 clinical trial.